258.29MMarket Cap-2.25P/E (TTM)
7.160High6.945Low319.41KVolume6.990Open6.980Pre Close2.25MTurnover1.16%Turnover RatioLossP/E (Static)36.53MShares18.75052wk High0.41P/B194.37MFloat Cap6.94052wk Low--Dividend TTM27.49MShs Float52.430Historical High--Div YieldTTM3.08%Amplitude6.940Historical Low7.051Avg Price1Lot Size
ITeos Therapeutics Stock Forum
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
Thursday, 12th December at 8:55 am
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts
- Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrat...
$ITeos Therapeutics (ITOS.US)$
$Montrose Environmental (MEG.US)$
$Nurix Therapeutics (NRIX.US)$
$Pearson (PSO.US)$
$UnitedHealth (UNH.US)$
$Option Care Health (OPCH.US)$
$Procter & Gamble (PG.US)$
$Montrose Environmental (MEG.US)$
$Nurix Therapeutics (NRIX.US)$
$Datadog (DDOG.US)$
$Pearson (PSO.US)$
$Procter & Gamble (PG.US)$
$Option Care Health (OPCH.US)$
$UnitedHealth (UNH.US)$
No comment yet